GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (FRA:NXOA) » Definitions » Construction In Progress

Nicox (FRA:NXOA) Construction In Progress : €0.00 Mil (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Nicox Construction In Progress?


Nicox Construction In Progress Historical Data

The historical data trend for Nicox's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Construction In Progress Chart

Nicox Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nicox Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nicox Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Nicox (FRA:NXOA) Business Description

Industry
Traded in Other Exchanges
Address
2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (FRA:NXOA) Headlines

No Headlines